Business Development Director, Medicines Patent Pool, Geneva, Switzerland
At the Medicines Patent Pool, Sandeep Juneja is responsible for its licence negotiations with
R&D and generic pharmaceutical companies for patented HIV medicines.
Previously, Mr. Juneja spent 17 years in the pharmaceutical industry mostly in developing
countries and in HIV and Malaria therapies.
He worked in various capacities such as starting
and running businesses, negotiating alliances, IP licensing and M&A.
Mr. Juneja was responsible for the entry of a major HIV drug supplier, Ranbaxy in that field.
He conceptualized and led Ranbaxy's HIV programme spanning over 60 countries, for 6
He was instrumental in development of new HIV formulations including first-in-theworld
paediatric combinations. He worked closely with stakeholders in the field and served in
advisory capacity on initiatives such as the Standing Committee on Universal Access, Global
Fund's Procurement Advisory Panel, and spoke regularly at HIV conferences especially on
issues relating to access to medicines.
Mr. Juneja has a Masters in International Business from the Indian Institute of Foreign Trade
and has a B.Tech in from the Indian Institute of Technology, Kanpur, India.
Addressing IP issues in Access to HIV Medicines ( 497KB)
International commitments to scale up of HIV treatment such as the 15x15, coupled with
changing patent regimes in key countries, necessitate addressing IP barriers on HIV
medicines in developing countries for continued access to contemporary HIV medicines
beyond first line drugs.
The Patent Pool addresses such barriers through licensing IP from
R&D pharmaceutical companies to generics to ensure development and manufacture of HIV
formulations adequate and appropriate for resource limited settings. The Pool being a
voluntary mechanism, faces challenges in incentive creation for some sections of the R&D
industry. EU and other stakeholders can have a role to play in strengthening motivation for
access friendly licensing by such industry members.